Summary & Overview
CPT 80430: Glucose and Growth Hormone Testing with Oral Glucose Challenge
CPT code 80430 represents a combined laboratory panel performed around an oral glucose challenge: glucose measured in three timed samples (one pre-glucose, two post-glucose) and human growth hormone measured in four timed samples (one pre-glucose, three post-glucose). This panel is used clinically to assess glucose metabolism and the suppression of growth hormone, commonly applied in evaluation of suspected endocrine disorders such as growth hormone excess or glucose regulatory abnormalities. Nationally, accurate use of this code affects laboratory billing, clinical pathway documentation, and reimbursement for time-sensitive, multi-sample endocrine testing.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what the code covers, typical sites of service, and clinical context for ordering the test. The publication also provides guidance on where to find benchmarks and policy updates, and summarizes common billing considerations associated with multi-sample endocrine testing. Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes is identified as missing in the detailed sections.
Billing Code Overview
CPT code 80430 describes laboratory measurement of glucose in three blood samples (one baseline, two post-glucose) combined with measurement of human growth hormone in four blood samples (one baseline, three post-glucose) collected around an oral glucose challenge. The service captures serial blood sampling and laboratory analysis to evaluate glucose regulation and growth hormone suppression dynamics.
-
Service type: Laboratory endocrine testing with oral glucose challenge
-
Typical site of service: Hospital outpatient laboratory or ambulatory clinical laboratory setting
Clinical & Coding Specifications
Clinical Context
A 28-year-old adult patient presents to an outpatient endocrine clinic with concerns of excessive growth, decreased energy, and abnormal glucose tolerance. The endocrinologist orders a combined oral glucose tolerance test with serial human growth hormone (GH) measurements to evaluate for growth hormone deficiency or excess and to assess glucose handling. On the day of testing the patient arrives fasting; a baseline blood sample is obtained for glucose and GH. The patient then ingests a standardized oral glucose load. Blood samples for glucose are collected at baseline (pre-glucose) and at two post-glucose time points per the protocol. For GH assessment, four samples are collected: one baseline and three post-glucose samples at specified intervals to evaluate GH suppression or stimulation. A laboratory phlebotomist performs timed draws; the lab analyst measures serum glucose in the three samples and measures human growth hormone in the four samples. Results are reported to the ordering endocrinologist for interpretation and follow-up, and the professional and technical components are billed according to facility and provider roles.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when only the physician interpretation/report is billed separately from the laboratory technical component. |
TC |